Wedbush Has Positive Outlook for CGEM FY2025 Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Wedbush boosted their FY2025 earnings per share estimates for Cullinan Therapeutics in a report released on Thursday, November 6th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($3.75) for the year, up from their previous estimate of ($4.08). The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.04) per share. Wedbush also issued estimates for Cullinan Therapeutics’ Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($0.97) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.67) EPS, FY2027 earnings at ($3.66) EPS, FY2028 earnings at ($3.51) EPS and FY2029 earnings at ($3.44) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.18.

CGEM has been the subject of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Cullinan Therapeutics in a report on Wednesday, October 8th. Zacks Research raised Cullinan Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 16th. Morgan Stanley dropped their price objective on shares of Cullinan Therapeutics from $35.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, August 18th. HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Cullinan Therapeutics in a report on Friday, September 12th. Finally, BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Cullinan Therapeutics in a report on Wednesday, September 10th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.00.

Cullinan Therapeutics Trading Down 2.2%

Shares of CGEM opened at $7.19 on Monday. Cullinan Therapeutics has a 12 month low of $5.68 and a 12 month high of $17.50. The company has a market capitalization of $424.74 million, a PE ratio of -2.17 and a beta of -0.07. The stock’s 50-day moving average price is $7.05 and its two-hundred day moving average price is $7.63.

Insider Activity

In other news, major shareholder Lynx1 Capital Management Lp purchased 165,667 shares of the company’s stock in a transaction dated Tuesday, October 28th. The shares were purchased at an average price of $8.40 per share, with a total value of $1,391,602.80. Following the transaction, the insider directly owned 8,963,500 shares of the company’s stock, valued at approximately $75,293,400. This represents a 1.88% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired 1,874,057 shares of company stock valued at $13,325,286 in the last 90 days. Insiders own 7.16% of the company’s stock.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CGEM. Brooklyn Investment Group purchased a new stake in Cullinan Therapeutics during the first quarter valued at about $34,000. SG Americas Securities LLC bought a new position in Cullinan Therapeutics in the 3rd quarter worth approximately $62,000. Tower Research Capital LLC TRC grew its stake in Cullinan Therapeutics by 44.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after buying an additional 2,523 shares in the last quarter. Inscription Capital LLC bought a new stake in Cullinan Therapeutics during the 3rd quarter valued at $67,000. Finally, Compass Ion Advisors LLC purchased a new stake in shares of Cullinan Therapeutics during the third quarter worth $82,000. 86.31% of the stock is currently owned by institutional investors.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.